Mark Suto
Suto and his team will focus on basic research and target identification and lead discovery and optimization of new therapies for cancer, infectious diseases and neurological diseases and disorders.
Prior to his appointment at SRI, Suto was VP, chemical and pharmaceutical sciences at Icagen.
“Mark Suto has demonstrated outstanding scientific and management skills in his career, and adds tremendous strength to our Drug Discovery program," said Jack Secrist, President and CEO.